These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 36992275)

  • 41. A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).
    Palkonyay L; Fatima H
    Vaccine; 2016 Oct; 34(45):5414-5419. PubMed ID: 27498212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How manufacturing won or lost the COVID-19 vaccine race.
    King ML
    Vaccine; 2024 Feb; 42(5):1004-1012. PubMed ID: 38228438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lessons learnt from COVID-19 to reduce mortality and morbidity in the Global South: addressing global vaccine equity for future pandemics.
    Martin R; Maleche A; Gay J; Fatima H
    BMJ Glob Health; 2024 Jan; 9(1):. PubMed ID: 38167259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can we move beyond vaccine apartheid? Examining the determinants of the COVID-19 vaccine gap.
    Forman L; Jackson C; Fajber K
    Glob Public Health; 2023 Jan; 18(1):2256822. PubMed ID: 37715686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil.
    Pagliusi S; Dennehy M; Homma A
    Vaccine; 2020 Aug; 38(36):5851-5860. PubMed ID: 32535016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward.
    Kumraj G; Pathak S; Shah S; Majumder P; Jain J; Bhati D; Hanif S; Mukherjee S; Ahmed S
    Hum Vaccin Immunother; 2022 Dec; 18(1):2020529. PubMed ID: 35086416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Race for COVID-19 Vaccines: Accelerating Innovation, Fair Allocation and Distribution.
    Daems R; Maes E
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Global regulatory reforms to promote equitable vaccine access in the next pandemic.
    Mahoney R; Hotez PJ; Bottazzi ME
    PLOS Glob Public Health; 2023; 3(10):e0002482. PubMed ID: 37851688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delayed Access to COVID-19 Vaccines: A Perspective on Low-income Countries in Africa.
    Hassan MA; Aliyu S
    Int J Health Serv; 2022 Jul; 52(3):323-329. PubMed ID: 35469499
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines.
    Neuzil KM; Bresee JS; de la Hoz F; Johansen K; Karron RA; Krishnan A; Madhi SA; Mangtani P; Spiro DJ; Ortiz JR;
    Vaccine; 2017 Oct; 35(43):5734-5737. PubMed ID: 28893473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy?
    Ferreccio C
    Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries.
    Pidiyar V; Kumraj G; Ahmed K; Ahmed S; Shah S; Majumder P; Verma B; Pathak S; Mukherjee S
    Vaccine; 2022 Aug; 40(36):5302-5312. PubMed ID: 35914959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Israeli health system's rapid responses during the COVID-19 pandemic.
    Rosen B; Hartal M; Waitzberg R
    Isr J Health Policy Res; 2024 Mar; 13(1):11. PubMed ID: 38438926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of global health partnerships in vaccine equity: A scoping review.
    Nunes C; McKee M; Howard N
    PLOS Glob Public Health; 2024; 4(2):e0002834. PubMed ID: 38386621
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
    Gaayeb L; Das A; James I; Murthy R; Nobre S; Burrone E; Morin S
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26092. PubMed ID: 37439078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Equitable and Feasible Distribution of SARS-CoV-2 Vaccines for All in Africa.
    Rogers AB; Barrie MB; Fallah MP; Kelly JD
    Am J Trop Med Hyg; 2021 Jun; 105(2):278-280. PubMed ID: 34181573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Dilemma, causes and countermeasures of global health governance: taking COVID-19 Vaccines Global Access Facility as an example].
    Bai AY; Zhang B; Jiang Y; Qiao Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Apr; 43(4):483-487. PubMed ID: 35443301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccine access, equity and justice: COVID-19 vaccines and vaccination.
    Privor-Dumm L; Excler JL; Gilbert S; Abdool Karim SS; Hotez PJ; Thompson D; Kim JH
    BMJ Glob Health; 2023 Jun; 8(6):. PubMed ID: 37290896
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical development and approval of COVID-19 vaccines.
    Kalinke U; Barouch DH; Rizzi R; Lagkadinou E; Türeci Ö; Pather S; Neels P
    Expert Rev Vaccines; 2022 May; 21(5):609-619. PubMed ID: 35157542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.